Research * Recherche
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis
M. Rodger, C. Bredeson, P. S. Wells, J. Beck, B. Kearns and L. B. Huebsch
CMAJ October 20, 1998 159 (8) 931-938;
M. Rodger
C. Bredeson
P. S. Wells
J. Beck
B. Kearns
In this issue
Article tools
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis
M. Rodger, C. Bredeson, P. S. Wells, J. Beck, B. Kearns, L. B. Huebsch
CMAJ Oct 1998, 159 (8) 931-938;
Related Articles
- No related articles found.
Cited By...
- Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy
- The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism: Outpatient versus inpatient management
- Low-molecular-weight heparin was more cost-effective than unfractionated heparin for treating deep venous thrombosis in several clinical settings